Capromab Biosimilar – Anti-FOLH2 mAb – Research Grade

Introduction to Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar – Anti-FOLH2 mAb is a monoclonal antibody (mAb) that specifically targets the folate hydrolase 2 (FOLH2) protein. This biosimilar is a research grade version of the original Capromab, which was approved by the US Food and Drug Administration (FDA) in 1996 for the detection of prostate cancer. The biosimilar version offers a more affordable option for research purposes and has the potential to be developed into a therapeutic antibody for the treatment of various cancers.

Structure of Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar – Anti-FOLH2 mAb is a recombinant humanized IgG1 monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the end of each arm and a constant fragment (Fc) at the base. The Fc region is responsible for the effector functions of the antibody, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar – Anti-FOLH2 mAb specifically binds to the FOLH2 protein, which is highly expressed on the surface of prostate cancer cells. The antibody recognizes a unique epitope on the FOLH2 protein and has a high affinity for it, allowing for efficient targeting and binding. This binding triggers a signaling cascade that leads to the activation of immune cells, resulting in the destruction of cancer cells through ADCC and CDC.

In addition to its diagnostic capabilities, Capromab Biosimilar – Anti-FOLH2 mAb has also shown promising results in preclinical studies as a therapeutic agent. It has been shown to inhibit the growth of prostate cancer cells and induce cell death through apoptosis. The antibody has also been found to enhance the effectiveness of chemotherapy and radiation therapy in prostate cancer treatment.

Application of Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar – Anti-FOLH2 mAb has a wide range of applications in both research and clinical settings. In research, the antibody can be used for the detection and quantification of FOLH2 expression in various cancer types, including prostate, bladder, and ovarian cancer. It can also be used to study the role of FOLH2 in cancer progression and to identify potential therapeutic targets.

In the clinical setting, Capromab Biosimilar – Anti-FOLH2 mAb has the potential to be developed into a therapeutic antibody for the treatment of prostate cancer and other FOLH2-expressing cancers. Its ability to specifically target cancer cells while sparing healthy cells makes it a promising candidate for cancer therapy. Additionally, the biosimilar version offers a more affordable option for patients and has the potential to increase access to this targeted treatment.

Conclusion

In summary, Capromab Biosimilar – Anti-FOLH2 mAb is a recombinant humanized monoclonal antibody that specifically targets the FOLH2 protein. It has a unique structure and high affinity for its target, making it an effective diagnostic and potentially therapeutic agent for various cancers. Its broad range of applications in research and clinical settings make it a valuable tool in the fight against cancer. With ongoing research and development, Capromab Biosimilar – Anti-FOLH2 mAb has the potential to improve cancer detection and treatment outcomes for patients.